List of Mounjaro drug patents

Mounjaro is owned by Eli Lilly And Co.

Mounjaro contains Tirzepatide.

Mounjaro has a total of 4 drug patents out of which 0 drug patents have expired.

Mounjaro was authorised for market use on 13 May, 2022.

Mounjaro is available in solution;subcutaneous dosage forms.

Mounjaro can be used as mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Drug patent challenges can be filed against Mounjaro from 2026-05-13.

The generics of Mounjaro are possible to be released after 14 June, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(7 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(8 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(16 years from now)

Do you want to check out MOUNJARO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 2026-05-13

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

MOUNJARO family patents

16

United States

8

Japan

6

China

EA

6

EA

6

European Union

5

Korea, Republic of

5

Israel

4

Brazil

4

Canada

4

Australia

3

Spain

3

Denmark

3

RS

3

Poland

3

Ukraine

3

Morocco

3

Croatia

3

Portugal

3

Jordan

3

Slovenia

2

Philippines

2

Singapore

2

Argentina

2

New Zealand

2

Cyprus

2

Peru

2

Chile

2

Taiwan

2

Mexico

2

Costa Rica

2

Ecuador

2

South Africa

2

Hungary

IB

1

IB

1

Hong Kong

1

Dominican Republic

1

Malaysia

1

Moldova, Republic of

1

Russia

1

ME

1

El Salvador

1

Colombia

1

Lithuania

1

Tunisia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic